Larimar Therapeutics, Inc. (LRMR) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Bala Cynwyd, PA, United States. The current CEO is Carole S. Ben-Maimon.
LRMR has IPO date of 2014-06-19, 65 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $416.77M.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
